title: Busulfan, fludarabine, and alemtuzumab conditioning and unrelated cord blood transplantation in children with sickle cell disease.
authors: Kavita
authors: K
authors: Radhakrishnan
authors: Monica
authors: M
authors: Bhatia
authors: Mark B
authors: MB
authors: Geyer
authors: Gustavo
authors: G
authors: Del Toro
authors: Zhezhen
authors: Z
authors: Jin
authors: Courtney
authors: C
authors: Baker
authors: Lauren
authors: L
authors: Harrison
authors: Erin
authors: E
authors: Morris
authors: Lee Ann
authors: LA
authors: Baxter-Lowe
authors: Mitchell S
authors: MS
authors: Cairo
mesh_terms: D000074323:Alemtuzumab; D000755:Anemia, Sickle Cell / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D002066:Busulfan / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D036101:Cord Blood Stem Cell Transplantation; D005260:Female; D006084:Graft Rejection; D006085:Graft Survival / Q000187:drug effects; D006801:Humans; D007223:Infant; D008297:Male; D019653:Myeloablative Agonists / Q000627:therapeutic use*; D019172:Transplantation Conditioning; D061349:Unrelated Donors; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D019653:Myeloablative Agonists; D000074323:Alemtuzumab; D014740:Vidarabine; D002066:Busulfan; C024352:fludarabine